Pfizer acquires Array Biopharma, valued at $11.4 billion
Tuesday, June 18, 2019, 7:33 AM
Pfizer Inc said it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs. The largest U.S. drugmaker agreed to pay a hefty premium of 62% for Array, which sells the combination treatment Braftovi and Mektovi for melanoma.
GSK to split after folding in Pfizer consumer unit
Wednesday, December 19, 2018, 7:56 PM
GlaxoSmithKline plans to split into two businesses one for prescription drugs and vaccines, the other for over-the-counter products after forming a new joint venture with Pfizer's consumer health division. In a bid to reassure investors of its financial strength, GSK extended its guarantee on the dividend by stating it expected to pay unchanged dividends of 80 pence per share for 2019.